Daniel Lyons, Ph.D., CFA
Daniel Lyons is a Portfolio Manager on the Health Care and Biotech Teams at Janus Henderson Investors, a role he has held since 2018. He is also a Research Analyst on the Healthcare team since 2000 and focuses on biotechnology and life science tools sectors. Daniel started consulting for Janus in 1997 and joined the research team full time in 2000.
Daniel received his bachelor of arts degree in biochemistry and chemistry from Rice University, graduating magna cum laude. He also earned a PhD from Stanford University’s programme in immunology and conducted postdoctoral research with a Nobel Laureate at the University of Colorado. He holds the Chartered Financial Analyst designation and has 24 years of financial industry experience.
Products Managed
Articles Written
Despite political headwinds, healthcare stocks stay anchored to innovation
Andy Acker and Dan Lyons say healthcare investors should expect volatility in 2025 – but also plenty of opportunities for long-term growth.
Healthcare stocks shine in a dimming economy
The sector’s traditionally defensive qualities and accelerating innovation could stand out amid a potentially slowing economy.
Will a new candidate create volatility for healthcare stocks?
Why we do not expect the last-minute change in the U.S. presidential election to lead to heightened volatility in healthcare stocks.
Biotech sector update: Going for gold
Amid interest rate cuts and accelerating innovation, the biotechnology sector could be set up for strong performance.
Why healthcare stocks could catch a break this election year
The sector has historically underperformed in the lead-up to U.S. presidential elections, but that may not be the case in 2024.
Healthcare’s small- and mid-cap opportunities amid aging populations
With populations in some of the largest economies quickly graying, innovative small- and mid-cap healthcare companies could deliver new growth opportunities for investors.
Biotech stocks gain momentum from lower rates, innovation, and M&A
Several factors are coming together that could help push the biotech sector higher.
Healthcare stocks: Positioned for a smoother ride in 2024?
Andy Acker and Dan Lyons share their outlook, saying a rapid pace of innovation and attractive valuations could propel the sector higher.
Global Perspectives: Healthcare’s underappreciated opportunities
How innovation, secular tailwinds – even regulation – are driving growth in the sector.